Kurkina NV, Repina EA, Volkova PV, Repin AA. Ibrutinib Efficacy in First-Line Therapy of High-Risk Patients Vs. Second- and Third-Line Therapies of Resistant Chronic Lymphocytic Leukemia. Clinical Oncohematology [Internet]. 2024 Feb. 20 [cited 2024 Dec. 12];16(2):209-12. Available from: https://bloodjournal.ru/index.php/coh/article/view/27